James E. Flynn - 27 Jun 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: 10%+ Owner
Issuer ticker: SPRY
Reported as of: 27 Jun 2025
Net transaction value: -$13,663,151
SEC form: 4
Accepted by SEC: 01 Jul 2025, 16:42:51 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 04 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Isler, Attorney-in-Fact

Key filing fact

James E. Flynn filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 01 Jul 2025.

Key facts

This page summarizes James E. Flynn's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2025, 16:42.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: -$13,663,151.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0001352546 Primary reporting owner

Flynn James E

Relationship: 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 01 Jul 2025

CIK 0001009258

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

Relationship: 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 01 Jul 2025

CIK 0001610540

Deerfield Mgmt III, L.P.

Relationship: 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 01 Jul 2025

CIK 0001603333

Deerfield Private Design Fund III, L.P.

Relationship: 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 01 Jul 2025

CIK 0001713467

Deerfield Mgmt IV, L.P.

Relationship: 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 01 Jul 2025

CIK 0001680307

Deerfield Private Design Fund IV, L.P.

Relationship: 10%+ Owner
Address: 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK
Signature: /s/ Jonathan Isler, Attorney-in-Fact
Signature date: 01 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRY transaction

Class A Common Stock

Sale

Transaction value: $6,831,584
Shares: -370,075
Change %: -7%
Price: $18.46
Shares after: 4,887,254
Date: 27 Jun 2025
Ownership: Through Deerfield Private Design Fund III, L.P.
Footnotes: F1, F2, F3

SPRY transaction

Class A Common Stock

Sale

Transaction value: $6,831,566
Shares: -370,074
Change %: -7%
Price: $18.46
Shares after: 4,887,254
Date: 27 Jun 2025
Ownership: Through Deerfield Private Design Fund IV, L.P.
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

James E. Flynn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.20 to $18.89, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

Footnote F2

This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (collectively with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P. and Deerfield Management Company, L.P.

Footnote F3

In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P. and James E. Flynn.